Cerevel Therapeutics

📍 Cambridge, United States🗓 Founded 2018👥 324 employees💰 Last funded Feb 2019
Pharmaceutical Manufacturing🌐 cerevel.com
Website LinkedIn
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Austria
1
Frequently asked questions
Who invested in Cerevel Therapeutics?
Cerevel Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Cerevel Therapeutics last raise funding?
The most recent investment in Cerevel Therapeutics recorded on gritt.io was in February 2019.
When was Cerevel Therapeutics founded?
Cerevel Therapeutics was founded in 2018.
What industry is Cerevel Therapeutics in?
Cerevel Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Cerevel Therapeutics based?
Cerevel Therapeutics is headquartered in Cambridge, United States.